Inhibikase Therapeutics, Inc. (IKT)
Valuation Overview•Is Inhibikase Therapeutics, Inc. Overvalued or Undervalued?
Popular:
Weak fundamentals — significant concerns
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.10 | $-0.10 | +0.0% | ||
| Q1'26 | $-0.12 | $-0.09 | +25.0% | ||
| Q4'25 | $-0.13 | $-0.13 | +0.0% | ||
| Q3'25 | $-0.09 | $-0.11 | -22.2% | ||
| Q2'25 | $-0.11 | $-0.15 | -36.4% | ||
| Q1'25 | $-0.10 | $-0.63 | -530.0% | ||
| Q4'24 | $-0.38 | $-0.65 | -71.1% | ||
| Q3'24 | $-0.58 | $-0.66 | -13.8% |
Total return, benchmark alpha, and annual history in one section.
3Y, 5Y, and 10Y use CAGR when available.
| Period | Return | vs S&P | Dividends |
|---|---|---|---|
| YTD | -14.4% | -22.3% | — |
| 1Y | -14.8% | -37.5% | — |
| 3YCAGR | -26.0% | -45.5% | — |
| 5YCAGR | -45.8% | -57.9% | — |
| 10YCAGR | -30.0% | -43.5% | — |
Year-by-year total return versus SPY, including dividend contribution.
| Year | Stock Return | SPY Return | Alpha | Dividends |
|---|---|---|---|---|
| 2026YTD | +5.1% | +0.4% | +4.7% | — |
| 2025 | -37.7% | +16.6% | -54.3% | — |
| 2024Best | +144.4% | +24.0% | +120.4% | — |
| 2023 | -60.9% | +24.8% | -85.7% | — |
| 2022 | -69.7% | -19.9% | -49.8% | — |
| 2021Worst | -78.9% | +28.8% | -107.7% | — |
| 2020 | -30.3% | +15.1% | -45.4% | — |
The S&P 500 is at 31.0x trailing P/E — Expensive relative to historical averages.
Based on our multi-model analysis of Inhibikase Therapeutics, Inc. (IKT) at $1.67: Fundamental quality score: 25/100 (below average). Wall Street consensus: Hold from 2 analysts. This is a quantitative summary combining DCF intrinsic value, peer-based relative valuation, quality scoring, and analyst consensus — not a buy/sell recommendation. Always consult a qualified financial advisor before investing.
Inhibikase Therapeutics, Inc. has multiple fair value estimates from different frameworks: Analyst consensus target: $4.00 (+139.5% upside, 2 analysts). We recommend comparing all three lenses — when DCF, relative, and analyst targets converge, the signal is stronger. When they diverge, investigate what assumptions differ.
Inhibikase Therapeutics, Inc.'s financial health as measured by our composite scoring: Overall quality score: 25/100. Piotroski F-Score: 2/9 (weak fundamentals). Altman Z-Score: 7.7 (safe zone — low bankruptcy risk). Return on invested capital: -108.0%. Cash conversion (OCF/NI): 0.58x (earnings exceed cash generation). The quality score blends profitability (ROIC, ROE, margins), solvency (leverage, coverage, Z-Score), and growth trajectory into a single 0–100 framework updated end-of-day.
Inhibikase Therapeutics, Inc.'s performance profile: 1-year total return: -14.8%. 1-year alpha vs S&P 500: -37.5% (underperforming the benchmark). 5-year CAGR: -45.8%. Maximum drawdown (1Y): -30.2%. Relative Strength rating: 49/99 (weak momentum). Beta: 1.98 (more volatile than the market). Total returns include reinvested dividends. Alpha is calculated against the S&P 500 Total Return Index over matching periods.
Inhibikase Therapeutics, Inc. does not currently pay a dividend or conduct significant share buybacks. The company is retaining capital for reinvestment.
Wall Street's outlook on Inhibikase Therapeutics, Inc.: Consensus rating: Hold from 2 covering analysts. Consensus price target: $4.00 (range: $4.00 to $4.00). Implied upside from current price: +139.5%. Earnings beat rate: 33%. Analyst estimates are blended into our proprietary model with weight based on coverage depth and historical accuracy. We track estimate revisions, beat rates, and grade changes daily.
Key risks identified for Inhibikase Therapeutics, Inc.: Drawdown risk: The stock experienced a -30.2% max drawdown in the past year. Volatility risk: Beta of 1.98 indicates significantly higher volatility than the broad market. Note: This model does not capture regulatory changes, management decisions, competitive disruption, or geopolitical events. Macro and qualitative risks remain material and should be assessed independently.
No. This overview dashboard aggregates data from our DCF intrinsic value model, relative peer multiples model, proprietary estimates engine, and third-party analyst consensus feeds. It is strictly for educational and informational purposes. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, quality scores, and signals are automated quantitative computations and should not be construed as investment recommendations. Consult a qualified, licensed financial advisor before making any investment decisions. Past model performance does not guarantee future results.